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Julian Downward
The Ras proteins are key mediators of the early 
cellular response to mitogens; the way in which they
influence the later events in the cell cycle is beginning
to fall into place.
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The Ras proteins are encoded by a closely related set of
genes, initially identified in acutely transforming sarcoma
viruses and subsequently in human tumour cell lines [1].
The transforming ras oncogenes are activated by point
mutation of the normal proto-oncogenes, so that they
encode a protein that is locked in the active, GTP-bound
state. As expression of a ras oncogene is sufficient to cause
transformed growth of established cell lines in culture, it is
clear that Ras can profoundly influence the passage of
cells through the cell cycle. Much has been learnt in the
past five years about the immediate signalling targets of
Ras: these include not only the well characterized
Raf/mitogen activated protein (MAP) kinase cascade, but
also phosphatidylinositol 3-kinase and the guanine
nucleotide exchange factor Ral-GDS [2]. It has remained
very unclear, however, how these Ras-controlled pathways
feed into regulation of the cell-cycle machinery. Recent
observations are beginning to shed light on this important
question, which has significance for our understanding of
both normal and transformed cell growth.
In addition to its transforming ability, the importance of Ras
in cell-cycle regulation has been established in several
ways. Seminal experiments showed that microinjection of
activated Ras protein into quiescent fibroblasts would cause
entry into S phase. The critical role of the endogenous Ras
protein in normal growth was established by microinjection
of neutralizing antibodies against Ras: this resulted in the
arrest of cells growing in serum. This treatment was also
able to inhibit the growth of fibroblasts that had been trans-
formed by oncogenes encoding tyrosine kinases. These
experiments, and others involving temperature-sensitive
mutant forms of Ras and cell-cycle inhibitors, suggested
that Ras function was required throughout G1 phase, but
that, once cells had entered S phase, Ras became dispens-
able until the next cell cycle [3,4], with the exception of a
possible requirement in G2 in some cell types and organ-
isms. The need for Ras function both early and late in G1 is
reminiscent of the well established model for cell-cycle
control by growth factors, in which ‘competence’ factors,
such as platelet-derived growth factor (PDGF), act to
release quiescent cells from the quiescent state, G0, while
‘progression’ factors found in plasma are required until a
‘restriction point’ is reached late in G1, at which time cells
become mitogen-independent [5,6].
Work over the past decade has established that the activa-
tion state of normal Ras proteins is regulated in response
to treatment of cells with a very wide variety of mitogens,
including what would normally be regarded as both com-
petence and progression factors. However, because of
technical limitations of the methods used to measure the
activation state of Ras, which relied on metabolic labelling
of cells with 32P-orthophosphate and subsequent immuno-
precipitation of Ras along with its bound nucleotide, the
stimulation of cells was usually only followed for short
periods, at most a couple of hours. Recently, a new
method has been perfected for measuring Ras activation
without the need for radioisotopic labelling, by affinity
precipitation using its target binding partner Raf, which
only binds to the active, GTP-bound form of Ras [7]. This
has allowed the activation state of Ras to be followed
throughout the cell cycle. 
The use of this new method showed that, unexpectedly,
in NIH 3T3 cells released from quiescence by treatment
with serum, the activation of Ras achieved rapidly after
serum addition is much less than a second activation some
five hours later in mid-G1 phase [7]. The mechanism
whereby this second peak of Ras activity is achieved is
unclear, but it appears to require protein synthesis and not
to use the well characterized pathway involving the linker
proteins Shc and Grb2, and the Ras nucleotide exchange
factor Sos, which mediates the short-term activation of Ras
by serum factors [8]. The mid-G1 peak of Ras activity may
explain the requirement for Ras function throughout most
of G1, and one might speculate that transition through the
restriction point does not occur until after this peak of Ras
activity has been reached. Interestingly, only the early
phase of Ras activation correlates with activation of the
Raf/MAP kinase pathway, while at later times high levels
of Ras–GTP occur without significant MAP kinase activ-
ity, possibly because that pathway is down-regulated by
inducible expression of specific phosphatases.
Although the signalling pathways acting immediately
downstream of Ras are reasonably well understood, as is the
basic cell-cycle machinery, the connections between the
two are still unclear. Recent work has begun to illuminate
this area. For example, activated Ras expression has been
shown to increase cyclin D1 expression levels and shorten
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G1 phase [9–11]. This effect appears to occur through the
Raf/MAP kinase pathway [12], which is stimulated by the
initial phase of Ras activation. It seems unlikely, however,
that cyclin D1 expression accounts for all the growth stimu-
lation provided by Ras, as cyclin D1 cooperates with acti-
vated Ras in transformation of primary murine cells under
some circumstances [13,14]. One of the principal targets of
the cyclin D-associated kinases, cyclin-dependent kinase 4
(Cdk4) and Cdk6, is the retinoblastoma tumour suppressor
protein (Rb); phosphorylation of Rb results in release of
bound E2F transcription factors, which play a key role in
transition from G1 to S phase.
Very recent work from Peeper et al. [15] and Mittnacht et al.
[16] shows that the ability of neutralizing antibodies against
Ras, or a dominant-negative mutant form of Ras, to inhibit
cell-cycle progression in asynchronously growing murine
fibroblasts depends on the presence of Rb. Cycling cells
lacking Rb fail to arrest when Ras function is inhibited,
although release of quiescent cells from G0 is inhibited by
dominant-negative Ras even in the absence of Rb. Expres-
sion of dominant-negative Ras causes loss of Rb phosphory-
lation, which can be corrected by forcing the expression of
cyclin D1. The ability to induce Rb phosphorylation
through cyclin D-dependent kinases is thus a major part of
the link between Ras and the cell-cycle machinery (Fig. 1).
It seems likely, however, that Rb does not account for all
aspects of Ras regulation of the cell cycle, as primary mouse
embryo fibroblasts lacking Rb are only partially protected
from the effects of inhibiting Ras. More complete effects
are seen in established cell lines, but this may be due to
other events that have occurred during cell culture. 
This illustrates a major problem with much of the work
done on Ras and the cell cycle — the variability of Ras
effects in different cell types, particularly in established
cell lines. For example, expression of activated Ras in
BALB c/3T3, but not NIH 3T3, cells fails to increase the
activity of Cdk4 and Cdk6, because of the presence of the
Cdk inhibitor p27Kip1 [11]. Ras by itself fails to induce S
phase in BALB c/3T3 cells, but does induce S phase in
NIH 3T3 cells. It has long been known that, unlike in
NIH 3T3 and similar cell lines which tend to have lost
some Cdk inhibitors, activated Ras alone will not transform
primary murine fibroblasts, Schwann cells or the REF52
cell line, but requires a cooperating oncogene to do so. By
itself, Ras causes growth arrest in these cells [17–19]. 
From recent work by Lloyd et al. [20], it is now apparent
that the growth inhibitory effect of Ras in Schwann cells is
due to the ability of the Raf/MAP kinase pathway to
induce expression of the Cdk inhibitor p21Cip1/Waf1.
Cooperating oncogenes, such as SV40 large T antigen,
block p53 function, which is required for induction of
p21Cip1/Waf1 expression, thus allowing activation of 
cyclin E-dependent kinase activity. Down-regulation of
p21Cip1/Waf1 with antisense oligonucleotides also relieves
growth arrest by Ras. It therefore appears that, in certain
primary cells, oncogenic Ras can induce Cdk inhibitor
expression by a p53-dependent pathway, providing an
explanation of oncogene cooperation, and perhaps also the
frequent occurrence of both Ras activation and p53 loss in
common human tumours such as colon carcinoma. Con-
versely, forcing the expression of high levels of the Cdk
inhibitors p16Ink4 [21] or p21Cip1/Waf1 [22] blocks the
Figure 1
Influence of Ras on G1 progression and S
phase entry. Two peaks of endogenous Ras
activity are seen, on release from G0 and
more strongly in mid G1. The first peak of Ras
activity may be responsible for cyclin D
induction via MAP kinase. The second peak of
Ras activity may act through other effectors to
influence later, unidentified events in mid-to-
late G1. Constitutively activated, oncogenic
Ras or Raf induce expression of the Cdk
inhibitor p21 via p53 to arrest primary
(Schwann) cells. Deletion of the gene
encoding Rb or the Cdk inhibitor p16 partially
removes the ability of a block in Ras function
to arrest primary cell-cycle progression,
implicating cyclin D as a major, though
probably not the only, cell-cycle target for
endogenous Ras. P in a white circle indicates
phosphorylation.
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ability of oncogenic Ras to cause proliferation and trans-
formation in murine fibroblast cell lines, whereas loss of
p16Ink4 allows Ras transformation of primary mouse
embryo fibroblasts [23].
A concern with the studies that try to establish the role of
Ras in normal cell-cycle regulation by using activated
mutant forms of Ras is that high levels of constitutively
activated Ras may behave differently from the relatively
low levels of activated Ras found in a normal cell. Further-
more, in the normal cell cycle, the Ras activation state
fluctuates with progression through the cycle [7]: it is not
inconceivable that the apparent ability of oncogenic Ras or
Raf to induce the expression of some Cdk inhibitors is a
protective or stress response of the cell to receiving a Ras
signal at an inappropriate stage in the cell cycle. 
This view is supported by recent work by Serrano et al.
[24] showing that expression of activated Ras in primary
mouse embryo fibroblasts, primary human diploid fibro-
blasts or REF52 cells causes growth arrest and premature
cellular senescence associated with increased expression
of p53 and p16Ink4. Inactivation of either p53 or p16Ink4
allows Ras to transform the mouse cells, rather than cause
senescence, but to achieve this in human cells, further loss
of tumour suppressor gene function is required; this can
be achieved by adenovirus E1A, which causes loss of both
Rb and p53 function. 
Thus, induction of cellular senescence is likely to be
another mechanism by which organisms can protect them-
selves from the damaging effects of activated oncogenes.
By contrast, Mittnacht et al. [16] found that cycling
primary mouse embryo fibroblasts lacking p16Ink4, but not
p21Cip1/Waf1, show partial protection from Ras-antibody-
induced cell-cycle arrest. Hence, loss of Cdk inhibitors
can release cells from cell-cycle arrest caused both by too
little Ras signal and also by too much Ras signal.
Although the work described above indicates that a major
point at which Ras controls the cell cycle is through regu-
lation of cyclin D expression, there is clearly reason to
think that this is not the whole story. The major peak of
Ras activation seen by Taylor and Shalloway [7] occurs
after cyclin D expression is already at a high level. Also,
this late Ras peak does not appear to be activating MAP
kinase, which has been implicated in the control of cyclin
D expression. What is the effect of activated Ras in mid-
G1 on cell-cycle progression? And what downstream effec-
tor pathway is Ras using? To what upstream signals is Ras
responding at this stage of the cell cycle? Ras at this point
may be more directly influencing later events in the cell
cycle, such as cyclin E or cyclin A expression, and could
be responding to environmental cues other than serum
factors. For example, Ras might be involved in the check-
point control that monitors cell adhesion late in G1 [25]. It
is possible that Ras is exerting its effects through the
phosphatidylinositol 3-kinase pathway, which is also
required for cell-cycle progression [26]. Whatever the
details, it is likely that the connections between Ras and
the control of both the normal and transformed cell cycle
will be greatly clarified in the near future.
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